CureVac indicates immune response from COVID-19 vaccine candidate
German biotech firm CureVac N.V. yesterday announced interim data from its ongoing Phase 1 dose-escalation study evaluating its CVnCoV SARS-CoV-2 vaccine candidate for safety, reactogenicity and immunogenicity.
CureVac said it has early indications that CVnCoV generates a balanced immune response, similar to that of natural COVID-19 infection. The drug maker said its data supports the beginning of a Phase 2b/3 clinical trial before the end of 2020 for a 12 microgram dose of the candidate.
Related News Articles
Headline
The Department of Health and Human Services Dec. 10 amended the Public Readiness and Emergency Preparedness Act declaration for COVID-19, extending liability…
Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…
Headline
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to…
Headline
The Centers for Medicare & Medicaid Services Oct. 22 released final guidance detailing reporting requirements for the hospital respiratory data condition…
Headline
The Centers for Disease Control and Prevention is reminding clinicians and other health care workers to take necessary steps to keep themselves and their…
Headline
The National Institutes of Health Oct. 10 released results of a study that found that infection from COVID-19 in the first wave of the pandemic appeared to…